New clinical trial aims to halt the progression of Alzheimer’s, says study

The studies hope to establish whether a drug called LMTX, can prevent the protein Tau from forming tangles, a commonly known cause of Alzheimer's disease.

The first study will involve 833 people with mild to moderate Alzheimer's disease over 12 months. The second will include 500 people with mild Alzheimer's disease over 18 months. Both trials will be conducted across fifteen counties, including the UK.

Alzheimer's Society comment:

'We know that tangles of Tau, a protein found in the brain, are a hallmark of Alzheimer's disease and cause brain cell death. Investigating drug treatments that have the potential to stop these tau tangles occurring is an interesting research avenue to explore.

'After hearing recently that drug companies are scaling back their research into treatments for Alzheimer's disease, it's really encouraging to see a study that has reached the clinical trial stage and that investment is still being made. There are currently 800,000 people living with dementia in the UK. With the right investment, dementia can be defeated.'

Jessica Smith
Research Officer
Alzheimer's Society

Further Information

• Key dementia statistics
• Progression of dementia